“Gilead Sciences will acquire biotech company Immunomedics in a $21 billion deal that will expand Gilead’s availability of cancer treatments, the companies announced on Sunday.  Shares of Immunomedics surged more than 100% in premarket trading Monday. The deal will provide Gilead access to the drug Trodelvy, a… Continue Reading…